Underexpression of peroxisome proliferator-activated receptor (PPAR)γ in PAX8/PPARγ-negative thyroid tumours

被引:0
|
作者
A R Marques
C Espadinha
M J Frias
L Roque
A L Catarino
L G Sobrinho
V Leite
机构
[1] Centro de Investigação de Patobiologia Molecular,
[2] Instituto Português de Oncologia Francisco Gentil,undefined
[3] Rua Professor Lima Basto,undefined
[4] Departamento de Patologia Morfológica,undefined
[5] Instituto Português de Oncologia Francisco Gentil,undefined
[6] Rua Professor Lima Basto,undefined
来源
British Journal of Cancer | 2004年 / 91卷
关键词
PPAR; PAX8; underexpression; follicular thyroid tumours;
D O I
暂无
中图分类号
学科分类号
摘要
The expression of peroxisome proliferator-activated receptor (PPAR)γ in thyroid neoplasias and in normal thyroid (NT) tissues has not been fully investigated. The objectives of the present work were: to study and compare the relative expression of PPARγ in normal, benign and malignant thyroid tissues and to correlate PPARγ immunostaining with clinical/pathological features of patients with thyroid cancer. We analysed the expression of PPARγ in several types of thyroid tissues by reverse transcription–polymerase chain reaction (RT–PCR), interphase fluorescent in situ hybridisation, real-time RT–PCR and immunohistochemistry. We have demonstrated that NT tissues express PPARγ both at mRNA and at protein level. PAX8-PPARγ fusion gene expression was found in 25% (six of 24) of follicular thyroid carcinomas (FTCs) and in 17% (six of 36) of follicular thyroid adenomas, but in none of the 10 normal tissues, 28 nodular hyperplasias, 38 papillary thyroid carcinomas (PTCs) and 11 poorly differentiated thyroid carcinomas (PDTCs). By real-time RT–PCR, we observed that tumours negative for the PAX8-PPARγ rearrangement expressed lower levels of PPARγ mRNA than the NT. Overexpression of PPARγ transcripts was detected in 80% (four of five) of translocation-positive tumours. Diffuse nuclear staining was significantly (P<0.05) less prevalent in FTCs (53%; 18 of 34), PTCs (49%; 19 of 39) and PDTCs (0%; zero of 13) than in normal tissue (77%; 36 of 47). Peroxisome proliferator-activated receptorγ-negative FTCs were more likely to be locally invasive, to persist after surgery, to metastasise and to have poorly differentiated areas. Papillary thyroid carcinomas with a predominantly follicular pattern were more often PPARγ negative than classic PTCs (80% vs 28%; P=0.01). Our results demonstrated that PPARγ is underexpressed in translocation-negative thyroid tumours of follicular origin and that a further reduction of PPARγ expression is associated with dedifferentiation at later stages of tumour development and progression.
引用
收藏
页码:732 / 738
页数:6
相关论文
共 50 条
  • [21] Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes
    Nicholls, Stephen J.
    Uno, Kiyoko
    DIABETES & VASCULAR DISEASE RESEARCH, 2012, 9 (02) : 89 - 94
  • [22] Role of peroxisome proliferator-activated receptor alpha (PPARα) and PPARα-mediated species differences in triclosan-induced liver toxicity
    Tang, Yangshun
    Vanlandingham, Michelle M.
    Wu, Yuanfeng
    Beland, Frederick A.
    Olson, Greg R.
    Fang, Jia-Long
    ARCHIVES OF TOXICOLOGY, 2018, 92 (11) : 3391 - 3402
  • [23] PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) - GAMMA IN METABOLIC SYNDROME: FRIENDS OR FOES?
    Vazquez Carrera, M.
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2005, 17 : 59 - 69
  • [24] Targeting the Tumor Stroma with Peroxisome Proliferator Activated Receptor (PPAR) Agonists
    Bundscherer, Annika
    Reichle, Albrecht
    Hafner, Christian
    Meyer, Stefanie
    Vogt, Thomas
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (07) : 816 - 821
  • [25] Peroxisome Proliferator-Activated Receptor (PPAR) Agonists as Promising New Medications for Drug Addiction: Preclinical Evidence
    Le Foll, Bernard
    Di Ciano, Patricia
    Panlilio, Leigh V.
    Goldberg, Steven R.
    Ciccocioppo, Roberto
    CURRENT DRUG TARGETS, 2013, 14 (07) : 768 - 776
  • [26] Evaluation of the Role of Peroxisome Proliferator-Activated Receptor (PPAR in Mouse Liver Tumor Induction by Trichloroethylene and Metabolites
    Corton, J. Christopher
    CRITICAL REVIEWS IN TOXICOLOGY, 2008, 38 (10) : 857 - 875
  • [27] Genetic variants of the peroxisome proliferator-activated receptor (PPAR) signaling pathway genes and risk of pancreatic cancer
    Liu, Xiaowen
    Qian, Danwen
    Liu, Hongliang
    Abbruzzese, James L.
    Luo, Sheng
    Walsh, Kyle M.
    Wei, Qingyi
    MOLECULAR CARCINOGENESIS, 2020, 59 (08) : 930 - 939
  • [28] It takes two peroxisome proliferator-activated receptors (PPAR-β/δ and PPAR-γ) to tango idiopathic pulmonary fibrosis
    Boateng, Eistine
    Bonilla-Martinez, Rocio
    Ahlemeyer, Barbara
    Garikapati, Vannuruswamy
    Alam, Mohammad Rashedul
    Trompak, Omelyan
    Oruqaj, Gani
    El-Merhie, Natalia
    Seimetz, Michael
    Ruppert, Clemens
    Guenther, Andreas
    Spengler, Bernhard
    Karnati, Srikanth
    Baumgart-Vogt, Eveline
    RESPIRATORY RESEARCH, 2024, 25 (01)
  • [29] Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) δ-selective agonists
    Kasuga, Jun-ichi
    Nakagome, Izumi
    Aoyama, Atsushi
    Sako, Kumiko
    Ishizawa, Michiyasu
    Ogura, Michitaka
    Makishima, Makoto
    Hirono, Shuichi
    Hashimoto, Yuichi
    Miyachi, Hiroyuki
    BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (15) : 5177 - 5190
  • [30] Genetic Variation in the Peroxisome Proliferator-Activated Receptor (PPAR) and Peroxisome Proliferator-Activated Receptor Gamma Co-activator 1 (PGC1) Gene Families and Type 2 Diabetes
    Villegas, Raquel
    Williams, Scott M.
    Gao, Yu-Tang
    Long, Jirong
    Shi, Jiajun
    Cai, Hui
    Li, Honglan
    Chen, Ching-Chu
    Tai, E. Shyong
    Hu, Frank
    Cai, Qiuyin
    Zheng, Wei
    Shu, Xiao-Ou
    ANNALS OF HUMAN GENETICS, 2014, 78 (01) : 23 - 32